article thumbnail

Opinion: Pharma’s ethically questionable sites essentially sell drugs directly to consumers

STAT

Some of the largest pharmaceutical companies in the U.S. This unprecedented move launches a new dystopic era: pharmaceutical companies as health care provider, no pesky physician middlemen needed. Want to self-prescribe a prescription drug? No problem!

article thumbnail

STAT+: A new list ranks large pharmaceutical companies by research and development

STAT

If you want a large pharmaceutical company to invent a new drug, your best bet is probably AstraZeneca. That’s the message from the 12th edition of the Pharmaceutical Innovation and Invention Index, produced by the consultancy Idea Pharma, which was released Thursday at the STAT Breakthrough Summit.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: As pharmaceutical companies bemoan Medicare’s drug negotiations, hospitals and doctors stay mum

STAT

The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

Hospitals 353
article thumbnail

Pharma’s big patent cliff, more obesity fundraising, and a failed ALS study

STAT

We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico. And what are the hosts’ New Year’s resolutions? Read the rest…

article thumbnail

STAT+: Truveta enlists health systems, drugmakers to launch ambitious new genomic database

STAT

The genetic data, cross-referenced with the patients’ de-identified medical records, will be available for purchase for researchers and life sciences companies. Pharmaceutical company Regeneron has invested $119.5

article thumbnail

STAT+: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds

STAT

Although more pharmaceutical companies are tailoring their business models to focus on low-income countries, a new analysis finds that overall industry efforts remain limited and patient access continues to suffer as a result.

article thumbnail

STAT+: Gilead plans to halt free access to an HIV drug, worrying patient advocates

STAT

Access to cheaper alternatives and low enrollment prompted the company to remove the medicine — along with the HIV medicines Emtriva, Tybost, and Complera — from its patent assistance program next month, according to an Oct. 8 letter that announced the move and that has not been widely reported.